Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:50 UTC |
---|
Update Date | 2022-03-07 02:51:42 UTC |
---|
HMDB ID | HMDB0014692 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Pentostatin |
---|
Description | Pentostatin is only found in individuals that have used or taken this drug. It is a potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. [PubChem]Pentostatin is a potent transition state inhibitor of adenosine deaminase (ADA), the greatest activity of which is found in cells of the lymphoid system. T-cells have higher ADA activity than B-cells, and T-cell malignancies have higher activity than B-cell malignancies. The cytotoxicity that results from prevention of catabolism of adenosine or deoxyadenosine is thought to be due to elevated intracellular levels of dATP, which can block DNA synthesis through inhibition of ribonucleotide reductase. Intracellular activation results in incorporation into DNA as a false purine base. An additional cytotoxic effect is related to its incorporation into RNA. Cytotoxicity is cell cycle phase-specific (S-phase). |
---|
Structure | OC[C@H]1O[C@H](C[C@@H]1O)N1C=NC2=C1N=CNC[C@H]2O InChI=1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9+/m0/s1 |
---|
Synonyms | Value | Source |
---|
Nipent | Kegg | 2'-DCF | HMDB | 2'-Deoxycoformycin | HMDB | 2'-Dexoycoformycin | HMDB | Deoxycoformycin | HMDB | CO-Vidarabine | HMDB | Lederle brand OF pentostatin | HMDB | Warner-lambert brand OF pentostatin | HMDB | Prasfarma brand OF pentostatin | HMDB | 2' Deoxycoformycin | HMDB | Co vidarabine | HMDB | Supergen brand OF pentostatin | HMDB | Wyeth brand OF pentostatin | HMDB | Pentostatin | KEGG |
|
---|
Chemical Formula | C11H16N4O4 |
---|
Average Molecular Weight | 268.2691 |
---|
Monoisotopic Molecular Weight | 268.11715502 |
---|
IUPAC Name | (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H,6H,7H,8H-imidazo[4,5-d][1,3]diazepin-8-ol |
---|
Traditional Name | pentostatin |
---|
CAS Registry Number | 53910-25-1 |
---|
SMILES | OC[C@H]1O[C@H](C[C@@H]1O)N1C=NC2=C1N=CNC[C@H]2O |
---|
InChI Identifier | InChI=1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9+/m0/s1 |
---|
InChI Key | FPVKHBSQESCIEP-JQCXWYLXSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as imidazodiazepines. These are organic compounds containing an imidazole ring fused to a diazepine ring. Imidazole is 5-membered ring consisting of three carbon atoms, and two nitrogen centers at the 1- and 3-positions. Diazepine is a 7-membered ring consisting of five carbon and two nitrogen atoms. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Imidazodiazepines |
---|
Sub Class | Not Available |
---|
Direct Parent | Imidazodiazepines |
---|
Alternative Parents | |
---|
Substituents | - Imidazo-meta-diazepine
- Imidazodiazepine
- Meta-diazepine
- N-substituted imidazole
- Azole
- Imidazole
- Heteroaromatic compound
- Tetrahydrofuran
- Secondary alcohol
- Amidine
- Formamidine
- Carboxylic acid amidine
- Oxacycle
- Azacycle
- Organic 1,3-dipolar compound
- Propargyl-type 1,3-dipolar organic compound
- Hydrocarbon derivative
- Organopnictogen compound
- Organonitrogen compound
- Organooxygen compound
- Primary alcohol
- Alcohol
- Organic nitrogen compound
- Organic oxygen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 220 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 10.7 g/L | Not Available | LogP | -1.1 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Pentostatin,1TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC3=C2N=CNC[C@H]3O)C[C@@H]1O | 2631.0 | Semi standard non polar | 33892256 | Pentostatin,1TMS,isomer #2 | C[Si](C)(C)O[C@H]1C[C@H](N2C=NC3=C2N=CNC[C@H]3O)O[C@@H]1CO | 2622.1 | Semi standard non polar | 33892256 | Pentostatin,1TMS,isomer #3 | C[Si](C)(C)O[C@@H]1CNC=NC2=C1N=CN2[C@H]1C[C@H](O)[C@@H](CO)O1 | 2559.7 | Semi standard non polar | 33892256 | Pentostatin,1TMS,isomer #4 | C[Si](C)(C)N1C=NC2=C(N=CN2[C@H]2C[C@H](O)[C@@H](CO)O2)[C@H](O)C1 | 2645.9 | Semi standard non polar | 33892256 | Pentostatin,2TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC3=C2N=CNC[C@H]3O[Si](C)(C)C)C[C@@H]1O | 2538.5 | Semi standard non polar | 33892256 | Pentostatin,2TMS,isomer #2 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC3=C2N=CNC[C@H]3O)C[C@@H]1O[Si](C)(C)C | 2549.7 | Semi standard non polar | 33892256 | Pentostatin,2TMS,isomer #3 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC3=C2N=CN([Si](C)(C)C)C[C@H]3O)C[C@@H]1O | 2618.7 | Semi standard non polar | 33892256 | Pentostatin,2TMS,isomer #4 | C[Si](C)(C)O[C@H]1C[C@H](N2C=NC3=C2N=CNC[C@H]3O[Si](C)(C)C)O[C@@H]1CO | 2536.1 | Semi standard non polar | 33892256 | Pentostatin,2TMS,isomer #5 | C[Si](C)(C)O[C@H]1C[C@H](N2C=NC3=C2N=CN([Si](C)(C)C)C[C@H]3O)O[C@@H]1CO | 2601.8 | Semi standard non polar | 33892256 | Pentostatin,2TMS,isomer #6 | C[Si](C)(C)O[C@@H]1CN([Si](C)(C)C)C=NC2=C1N=CN2[C@H]1C[C@H](O)[C@@H](CO)O1 | 2603.7 | Semi standard non polar | 33892256 | Pentostatin,3TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC3=C2N=CNC[C@H]3O[Si](C)(C)C)C[C@@H]1O[Si](C)(C)C | 2514.4 | Semi standard non polar | 33892256 | Pentostatin,3TMS,isomer #2 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC3=C2N=CN([Si](C)(C)C)C[C@H]3O[Si](C)(C)C)C[C@@H]1O | 2585.9 | Semi standard non polar | 33892256 | Pentostatin,3TMS,isomer #3 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC3=C2N=CN([Si](C)(C)C)C[C@H]3O)C[C@@H]1O[Si](C)(C)C | 2573.9 | Semi standard non polar | 33892256 | Pentostatin,3TMS,isomer #4 | C[Si](C)(C)O[C@H]1C[C@H](N2C=NC3=C2N=CN([Si](C)(C)C)C[C@H]3O[Si](C)(C)C)O[C@@H]1CO | 2574.4 | Semi standard non polar | 33892256 | Pentostatin,4TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC3=C2N=CN([Si](C)(C)C)C[C@H]3O[Si](C)(C)C)C[C@@H]1O[Si](C)(C)C | 2572.6 | Semi standard non polar | 33892256 | Pentostatin,4TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC3=C2N=CN([Si](C)(C)C)C[C@H]3O[Si](C)(C)C)C[C@@H]1O[Si](C)(C)C | 2705.2 | Standard non polar | 33892256 | Pentostatin,4TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC3=C2N=CN([Si](C)(C)C)C[C@H]3O[Si](C)(C)C)C[C@@H]1O[Si](C)(C)C | 4353.1 | Standard polar | 33892256 | Pentostatin,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC3=C2N=CNC[C@H]3O)C[C@@H]1O | 2861.4 | Semi standard non polar | 33892256 | Pentostatin,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)O[C@H]1C[C@H](N2C=NC3=C2N=CNC[C@H]3O)O[C@@H]1CO | 2845.4 | Semi standard non polar | 33892256 | Pentostatin,1TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)O[C@@H]1CNC=NC2=C1N=CN2[C@H]1C[C@H](O)[C@@H](CO)O1 | 2784.5 | Semi standard non polar | 33892256 | Pentostatin,1TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)N1C=NC2=C(N=CN2[C@H]2C[C@H](O)[C@@H](CO)O2)[C@H](O)C1 | 2856.8 | Semi standard non polar | 33892256 | Pentostatin,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC3=C2N=CNC[C@H]3O[Si](C)(C)C(C)(C)C)C[C@@H]1O | 2964.5 | Semi standard non polar | 33892256 | Pentostatin,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC3=C2N=CNC[C@H]3O)C[C@@H]1O[Si](C)(C)C(C)(C)C | 3009.9 | Semi standard non polar | 33892256 | Pentostatin,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC3=C2N=CN([Si](C)(C)C(C)(C)C)C[C@H]3O)C[C@@H]1O | 3040.6 | Semi standard non polar | 33892256 | Pentostatin,2TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)O[C@H]1C[C@H](N2C=NC3=C2N=CNC[C@H]3O[Si](C)(C)C(C)(C)C)O[C@@H]1CO | 2950.8 | Semi standard non polar | 33892256 | Pentostatin,2TBDMS,isomer #5 | CC(C)(C)[Si](C)(C)O[C@H]1C[C@H](N2C=NC3=C2N=CN([Si](C)(C)C(C)(C)C)C[C@H]3O)O[C@@H]1CO | 3044.3 | Semi standard non polar | 33892256 | Pentostatin,2TBDMS,isomer #6 | CC(C)(C)[Si](C)(C)O[C@@H]1CN([Si](C)(C)C(C)(C)C)C=NC2=C1N=CN2[C@H]1C[C@H](O)[C@@H](CO)O1 | 3016.4 | Semi standard non polar | 33892256 | Pentostatin,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC3=C2N=CNC[C@H]3O[Si](C)(C)C(C)(C)C)C[C@@H]1O[Si](C)(C)C(C)(C)C | 3129.6 | Semi standard non polar | 33892256 | Pentostatin,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC3=C2N=CN([Si](C)(C)C(C)(C)C)C[C@H]3O[Si](C)(C)C(C)(C)C)C[C@@H]1O | 3219.2 | Semi standard non polar | 33892256 | Pentostatin,3TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC3=C2N=CN([Si](C)(C)C(C)(C)C)C[C@H]3O)C[C@@H]1O[Si](C)(C)C(C)(C)C | 3228.9 | Semi standard non polar | 33892256 | Pentostatin,3TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)O[C@H]1C[C@H](N2C=NC3=C2N=CN([Si](C)(C)C(C)(C)C)C[C@H]3O[Si](C)(C)C(C)(C)C)O[C@@H]1CO | 3225.5 | Semi standard non polar | 33892256 | Pentostatin,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC3=C2N=CN([Si](C)(C)C(C)(C)C)C[C@H]3O[Si](C)(C)C(C)(C)C)C[C@@H]1O[Si](C)(C)C(C)(C)C | 3410.2 | Semi standard non polar | 33892256 | Pentostatin,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC3=C2N=CN([Si](C)(C)C(C)(C)C)C[C@H]3O[Si](C)(C)C(C)(C)C)C[C@@H]1O[Si](C)(C)C(C)(C)C | 3540.0 | Standard non polar | 33892256 | Pentostatin,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC3=C2N=CN([Si](C)(C)C(C)(C)C)C[C@H]3O[Si](C)(C)C(C)(C)C)C[C@@H]1O[Si](C)(C)C(C)(C)C | 4476.9 | Standard polar | 33892256 |
|
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Pentostatin GC-MS (Non-derivatized) - 70eV, Positive | splash10-000f-9280000000-53989a5cd0535c5bb1c0 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Pentostatin GC-MS (3 TMS) - 70eV, Positive | splash10-0g4i-5556900000-faa1467da14d5869f1a4 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Pentostatin GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Pentostatin GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentostatin 10V, Positive-QTOF | splash10-0udr-0920000000-59e330d7bf2bc1680990 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentostatin 20V, Positive-QTOF | splash10-0udr-0900000000-e3af78d60d01def1ac1a | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentostatin 40V, Positive-QTOF | splash10-0f79-1900000000-d626d4471ad700c9f0d6 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentostatin 10V, Negative-QTOF | splash10-014i-0390000000-b18e6406ad078d5394a4 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentostatin 20V, Negative-QTOF | splash10-0udi-0910000000-bc5d8c218c955e8890bd | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentostatin 40V, Negative-QTOF | splash10-05ai-9400000000-3516f2a449bec4f6eab1 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentostatin 10V, Positive-QTOF | splash10-0udi-0900000000-72c3636a284833d70d68 | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentostatin 20V, Positive-QTOF | splash10-000i-0900000000-0ed9eb4f7ab63001c261 | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentostatin 40V, Positive-QTOF | splash10-000i-0900000000-37329b69923f607d6e79 | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentostatin 10V, Negative-QTOF | splash10-0udi-0920000000-91b2100cdc647d86ee1c | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentostatin 20V, Negative-QTOF | splash10-0udi-0900000000-5db12e941598533606e0 | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentostatin 40V, Negative-QTOF | splash10-001i-0900000000-38150a6439ac940dede9 | 2021-09-25 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00552 | | details | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00552 | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Predicted Concentrations |
---|
| |
Blood | 0.000 uM | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities | Blood | 0.000 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities |
|
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB00552 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 388759 |
---|
KEGG Compound ID | C02267 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Pentostatin |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 439693 |
---|
PDB ID | DCF |
---|
ChEBI ID | Not Available |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Mercieca J, Matutes E, Moskovic E, MacLennan K, Matthey F, Costello C, Behrens J, Basu S, Roath S, Fairhead S, et al.: Massive abdominal lymphadenopathy in hairy cell leukaemia: a report of 12 cases. Br J Haematol. 1992 Nov;82(3):547-54. [PubMed:1283078 ]
- Schwartz CL, Minniti CP, Harwood P, Na S, Banquerigo ML, Strauss LC, Kurtzberg J, Smith SD, Civin CI: Elimination of clonogenic malignant human T cells using monoclonal antibodies in combination with 2'-deoxycoformycin. J Clin Oncol. 1987 Dec;5(12):1900-11. [PubMed:3500279 ]
- Thaler J, Denz H, Dietze O, Gastl G, Ho AD, Gattringer C, Greil R, Lechleitner M, Huber C, Huber H: Immunohistological assessment of bone marrow biopsies from patients with hairy cell leukemia: changes following treatment with alpha-2-interferon and deoxycoformycin. Leuk Res. 1989;13(5):377-83. [PubMed:2787447 ]
- Ruers TJ, Buurman WA, van der Linden CJ: 2'Deoxycoformycin and deoxyadenosine affect IL 2 production and IL 2 receptor expression of human T cells. J Immunol. 1987 Jan 1;138(1):116-22. [PubMed:3097141 ]
- Lembersky BC, Golomb HM: Hairy cell leukemia: clinical features and therapeutic advances. Cancer Metastasis Rev. 1987;6(3):283-300. [PubMed:2446791 ]
- Sainati L, Matutes E, Mulligan S, de Oliveira MP, Rani S, Lampert IA, Catovsky D: A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients. Blood. 1990 Jul 1;76(1):157-62. [PubMed:2364167 ]
- Okamura K, Ikeda T, Shimakura Y, Yoshiba F, Kishi K, Ando K, Hotta T: [Allogeneic bone marrow transplantation for chemotherapy-resistant T-prolymphocytic leukemia]. Rinsho Ketsueki. 2005 Jul;46(7):527-31. [PubMed:16440747 ]
- Mughal TI, Goldman JM: Chronic leukaemias: can they be cured? Part II: Chronic lymphocytic leukaemia. Br J Clin Pract. 1989 Oct;43(10):353-6. [PubMed:2698240 ]
- O'Dwyer PJ, Cheson BD, Leyland-Jones B, King SA, Hoth DF: Deoxycoformycin: an active new drug for indolent lymphomas and hairy cell leukemia. Oncology (Williston Park). 1988 Jun;2(6):17-23, 26-7. [PubMed:3079330 ]
- Bethlenfalvay NC, Lima JE, Banks RE: 2'-Deoxyadenosine metabolism in human and opossum Didelphis virginiana erythrocytes in vitro. Comp Biochem Physiol B. 1993 Nov;106(3):641-5. [PubMed:8281758 ]
- Dillman RO, Yu AL, Qiao CN: Repeated pentostatin (2'deoxycoformycin)-induced remissions in a patient with advanced chronic lymphocytic leukemia. West J Med. 1988 Mar;148(3):334-7. [PubMed:3259051 ]
- Catovsky D, Matutes E, Talavera JG, O'Connor NT, Johnson SA, Emmett E, Corbett L, Swansbury J: Long term results with 2'deoxycoformycin in hairy cell leukemia. Leuk Lymphoma. 1994;14 Suppl 1:109-13. [PubMed:7820041 ]
- Thaler J, Dietze O, Faber V, Greil R, Gastl G, Denz H, Ho AD, Huber H: Monoclonal antibody B-ly7: a sensitive marker for detection of minimal residual disease in hairy cell leukemia. Leukemia. 1990 Mar;4(3):170-6. [PubMed:2314116 ]
- Ho AD, Thaler J, Willemze R, Lauria F, Derossi G, Kuse R, Stryckmans P, Blanc CM, Cataldo F, McVie G, et al.: Pentostatin (2'deoxycoformycin) for the treatment of lymphoid neoplasms. Bone Marrow Transplant. 1989 Jan;4 Suppl 1:60-2. [PubMed:2653520 ]
- Romo A, Lorente F, Salazar V: Action of 2'-deoxycoformycin on mitogen-induced lymphoproliferation in the neonatal period. Allergol Immunopathol (Madr). 1988 Jul-Aug;16(4):243-7. [PubMed:3265855 ]
- Roth E Jr, Ogasawara N, Schulman S: The deamination of adenosine and adenosine monophosphate in Plasmodium falciparum-infected human erythrocytes: in vitro use of 2'deoxycoformycin and AMP deaminase-deficient red cells. Blood. 1989 Aug 15;74(3):1121-5. [PubMed:2665862 ]
- Mante S, Minneman KP: Is adenosine involved in inhibition of forskolin-stimulated cyclic AMP accumulation by caffeine in rat brain? Mol Pharmacol. 1990 Nov;38(5):652-9. [PubMed:2172772 ]
- Fabian I, Williams Z: The effect of deoxycoformycin on bone marrow cells treated with adenosine and deoxyadenosine and hemopoietic growth factors. Hum Immunol. 1988 Feb;21(2):81-7. [PubMed:3259223 ]
- Montgomery RB, Kurtzberg J, Rhinehardt-Clark A, Haleen A, Ramakrishnan S, Olsen GA, Peters WP, Smith CA, Haynes BF, Houston LL, et al.: Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin. Bone Marrow Transplant. 1990 Jun;5(6):395-402. [PubMed:2369680 ]
- BC Cancer Agency [Link]
|
---|